Drug intelligence / Profile preview

mecamylamine + antidepressant

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

**mecamylamine + antidepressant** refers to the combination of the nicotinic acetylcholine receptor antagonist **mecamylamine** with an **antidepressant**, typically a selective serotonin reuptake inhibitor (SSRI) or another established antidepressant medication, as an experimental therapeutic approach for treatment-resistant depression. Mecamylamine, originally used for hypertension, blocks nicotinic acetylcholine receptors and has been studied for its potential to augment antidepressant effects, particularly as an adjunct in patients who have not responded to SSRIs alone. Preclinical and early clinical evidence suggest that mecamylamine can enhance serotonergic neurotransmission and may potentiate or alter the efficacy of antidepressants[2][6][7].

02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)CHRNA7 (α7 nicotinic receptor)

Beyond the preview

Go deeper on mecamylamine + antidepressant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mecamylamine + antidepressant.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call